323 related articles for article (PubMed ID: 15652378)
1. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
2. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew).
Darmani NA; Zhao W; Ahmad B
J Neural Transm (Vienna); 1999; 106(11-12):1045-61. PubMed ID: 10651102
[TBL] [Abstract][Full Text] [Related]
3. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
4. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
5. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
6. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
7. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).
Kwiatkowska M; Parker LA; Burton P; Mechoulam R
Psychopharmacology (Berl); 2004 Jul; 174(2):254-9. PubMed ID: 14740147
[TBL] [Abstract][Full Text] [Related]
9. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
10. The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.
Wang Y; Ray AP; McClanahan BA; Darmani NA
Pharmacol Biochem Behav; 2009 Jan; 91(3):367-73. PubMed ID: 18727934
[TBL] [Abstract][Full Text] [Related]
11. Broad-spectrum antiemetic efficacy of the L-type calcium channel blocker amlodipine in the least shrew (Cryptotis parva).
Zhong W; Chebolu S; Darmani NA
Pharmacol Biochem Behav; 2014 May; 120():124-32. PubMed ID: 24631485
[TBL] [Abstract][Full Text] [Related]
12. Ultra-low doses of the transient receptor potential vanilloid 1 agonist, resiniferatoxin, prevents vomiting evoked by diverse emetogens in the least shrew (Cryptotis parva).
Darmani NA; Henry DA; Zhong W; Chebolu S
Behav Pharmacol; 2020 Feb; 31(1):3-14. PubMed ID: 31503071
[TBL] [Abstract][Full Text] [Related]
13. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
14. Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.
Ray AP; Griggs L; Darmani NA
Behav Brain Res; 2009 Jan; 196(1):30-6. PubMed ID: 18721829
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction pathways involved in dopamine D
Belkacemi L; Zhong W; Darmani NA
Auton Neurosci; 2021 Jul; 233():102807. PubMed ID: 33865060
[TBL] [Abstract][Full Text] [Related]
17. The pivotal role of glycogen synthase kinase 3 (GSK-3) in vomiting evoked by specific emetogens in the least shrew (Cryptotis parva).
Zhong W; Darmani NA
Neurochem Int; 2020 Jan; 132():104603. PubMed ID: 31738972
[TBL] [Abstract][Full Text] [Related]
18. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
19. Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
Darmani NA; Wang Y; Abad J; Ray AP; Thrush GR; Ramirez J
Brain Res; 2008 Jun; 1214():58-72. PubMed ID: 18471804
[TBL] [Abstract][Full Text] [Related]
20. Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (
Belkacemi L; Sun Y; Darmani NA
Front Pharmacol; 2022; 13():848673. PubMed ID: 35444553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
